Search for content, post, videos
Advertisement

Alligator announces positive second Phase 2 interim results

Søren Bregenholt

Alligator Bioscience has announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer.

The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb agonist) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.

With our planned discussions with regulators and the expected top-line readout from OPTIMIZE-1 due at the beginning of next year, we continue to make excellent progress with the clinical development of mitazalimab and its route to market.”

“Our OPTIMIZE-1 Phase 2 study has produced another set of very encouraging data to add to the growing body of compelling clinical evidence supporting our lead drug candidate mitazalimab in pancreatic cancer. Especially, we are excited to see that tumor responses continue to develop suggesting a longer benefit for the patients, and we are looking forward to seeing the data from the full cohort mature as the trial progress,” said Søren Bregenholt, CEO of Alligator Bioscience. “With our planned discussions with regulators and the expected top-line readout from OPTIMIZE-1 due at the beginning of next year, we continue to make excellent progress with the clinical development of mitazalimab and its route to market.”

The second interim analysis conducted on the 23 patients included in the interim analysis reported in January 2023, with a follow-up period of nine to 17 months demonstrated that the tumor responses deepened and the Objective Response Rate (ORR) increased to 57% (from 52%), suggesting a durable benefit for patients. Of the 13 patients achieving an objective response, seven (54%) were still ongoing in treatment for longer than 10 months with a maintained response, with the longest being 17 months. The interim analysis conducted on all 57 evaluable patients with a follow-up period of two to 17 months demonstrated the following:

25 patients responded to treatment resulting in an interim ORR of 44%. Median Duration of Response (DoR) was 8.7 months compared to 5.9 reported for FOLFIRINOX alone in other studies, indicating an immunostimulatory effect of mitazalimab and potential Progression Free Survival (PFS) and survival benefits. In addition, 19 patients (33%) achieved stable disease resulting in a 77% disease control rate (DCR). Furthermore, mitazalimab’s manageable safety and tolerability profile in combination with mFOLFIRINOX was confirmed. In both interim analyses, patients were evaluated as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

These data compare favorably to the ORR of 31.6%, mPFS of 6.4 months and DoR of 5.9 months reported in similar patient populations treated with standard of care FOLFIRINOX alone.

Top-line readout in early Q1 2024

Completion of patient enrolment in OPTIMIZE-1 was reported in April 2023, and in May 2023, mitazalimab was granted Orphan Drug Designation by the U. S. Food and Drug Administration for the treatment of pancreatic cancer.

These data will form the basis of discussions with regulators in the U.S. and Europe on the optimal development and approval pathway for mitazalimab in pancreatic cancer, states the company.

OPTIMIZE-1 remains on track for top-line readout in early Q1 2024.

Photo of Søren Bregenholt: Alligator